COSM C mutations reduce T-synthase activity in advanced Alzheimer’s disease

Seema Gollamudi | Rukmani Lekhraj | Shirin Lalezari | Parviz Lalezari

Neurosurgery Research Laboratory, Department of Neurosurgery, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA

Correspondence
Parviz Lalezari, Montefiore Medical Center, 111 East 210 Street, Neurosurgery Research Laboratory, Moses Research Tower, 3rd Floor, Bronx, NY 10467, USA. Email: lalezari2@aol.com

Abstract
Introduction: Mutations in brain tissues that cumulate with age may contribute to Alzheimer’s disease (AD). Abnormal glycoprotein and Tn antigen expression have been demonstrated in AD. We identified C1GALT1/COSM C mutations in AD and age-matched normals without AD. The COSMC coding mutations resulted in a significant reduction in T-synthase activity in advanced AD cases.

Methods: Identification of COSMC mutations, Real-Time Quantitative Reverse Transcription PCR (Q-RT-PCR), western blotting, and T-synthase activity assays.

Results: COSMC mutations were detected in the promotor, coding region and 3′UTR in AD and normals. COSMC coding mutations demonstrated a correlation with AD progression. T-synthase levels were significantly elevated in advanced AD compared to AD III (P = 0.03) and normals (P = 0.002). T-synthase activity in advanced AD [Braak and Braak (B&B) stages V and VI] with COSMC coding mutations was 3-fold lower than advanced AD without mutations, and 1.3-fold lower than normal (P = 0.001) and AD B&B stage III (P = 0.01) with coding mutations.

Discussion: COSMC coding mutations significantly diminished T-synthase activity in advanced AD, potentially causing defective galactosylation.

KEYWORDS
brain, C1GALT1/T-synthase, COSMC/C1GALT1C1, late-onset Alzheimer’s disease, mutations

1 | INTRODUCTION

Since the discovery of Alzheimer’s disease (AD) there have been many explorations to determine its pathogenesis. AD is classified as early onset (EOAD, ≤65 years) and late-onset (LOAD, >65 years).1 In EOAD, which affects 5% of AD population, three autosomal dominant genes—amyloid precursor protein (APP), presenilin 1, and presenilin 2—are involved in the pathogenesis.2 Genetic factors are considered to play a role in the pathogenesis of LOAD, but since their mechanisms of action are unknown, they are considered risk factors. These include polymorphisms in apolipoprotein E gene ε4 alleles, methylenetetrahydrofolate reductase, and brain-derived neurotrophic factor.3,4 AD in different forms has a substantial but heterogeneous genetic component, and additional genetic factors remain to be identified.

The role of glycoprotein abnormalities in AD pathogenesis has been the focus of recent studies in this and other laboratories.5-7 In normal core-1 glycosylation, N-acetylgalactosamine (GalNac) is capped by galactose and sialic acid.8,9 Transfer of galactose to GalNac is mediated by C1GALT1/T-synthase enzyme, followed by the terminal addition of sialic acid.10,11 The activity of T-synthase depends on the molecular chaperone C1GALT1C1/COSMC.12 COSMC is required for folding, stability, and activity of T-synthase, and its disruption in mice results in...
Nucleic acid extractions

Polymerase chain reaction and Sanger

2  |  METHODS

2.1  |  Human brain tissue

Frozen cortical samples from AD and age-matched normal brains were obtained from Kathleen Price Bryan Brain Bank of Duke University Medical Center, NC, USA, and from New South Wales (NSW) Tissue Resource Centre at the University of Sydney and the Sydney Brain Bank at Neuroscience Research Australia which are supported by the National Health and Medical Research Council of Australia, The University of New South Wales, Neuroscience Research Australia and Schizophrenia Research Institute. Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R28AA012725. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This study was approved by the institutional review board of Albert Einstein College of Medicine (AEcom), NY, USA vide number 2018-9204. The age, gender, postmortem delay, and Braak and Braak stages can be found in Supplementary Table 1. These include nine normal, five AD stage III (AD III), five AD stage V (AD V), and six AD stage VI (AD VI) samples. The AD V and AD VI were combined for analysis and have been labeled as AD VI-1 through AD VI-11 and collectively referred to as advanced AD. Control samples from age-matched donors without AD manifestation are referred as normals.

RESEARCH IN CONTEXT

1. Systematic review: During core-1 biosynthesis, GalNAc-linked to Ser/Thr, is capped by galactose forming Gal[β3GalNAc1-Ser/Thr (T-antigen). Transfer of galactose to GalNAc is catalyzed by C1GALT1/T-synthase that requires a molecular chaperone C1GALT1C1/COSMC. We tested Alzheimer’s disease (AD) and age-matched normal brains tissues for COSMC mutations and their effects on COSMC and T-synthase protein levels, and on T-synthase activity.

2. Interpretation: Multiple COSMC mutations were detected in all groups. In advanced AD, COSMC coding mutations led to a significant reduction in T-synthase activity without significant effects on COSMC, although significantly elevating T-synthase protein levels suggesting reduced COSMC chaperone activity. Dysfunctions caused by COSMC mutations may initiate aberrant galactosylation in advanced AD.

3. Future directions: It is necessary to identify brain cells and regions in which COSMC mutations occur, to test larger number of samples, determine somatic or hereditary nature of the mutations, and establish their association and role in glycoproteome alterations and pathogenesis of AD.

2.2  |  Nucleic acid extractions

DNA and RNA from frozen brain tissues were extracted using DNeasy Blood and Tissue Kit (Qiagen, USA) and Trizol reagent (Invitrogen, USA) respectively. DNA and RNA concentrations were measured using a nanodrop ND-1000 spectrophotometer (Thermo Scientific, USA).

2.3  |  Polymerase chain reaction and Sanger sequencing

Polymerase chain reaction (PCR) was carried out in 25 μL volume using 500 ng DNA, AmpliTaq Gold 360 master mix (Applied Biosystems Inc.,
USA), C1GALT1C1 gene specific primers for the two exons (RefSeq NM_001011551) in a MJ Research PTC-200 Thermal Cycler (Biorad Laboratories Inc., USA) at 59°C annealing temperature. The forward and reverse primers for exon 1 were pF1: 5′ACGCAGGCTCTATAGCAATCC′3′ and pR1: 5′TCCTGTGCTGACAATCTCC′3′. Exon 2 was amplified using two overlapping primer pairs to span the entire length. The two forward primers were pF2a: 5′TGATTCTAAGCTTGGAGACCTTT′3′ and pF2b: 5′TGAAAATATGGCAAATGCTC′3′, and the two reverse primers were pR2a: 5′TGAGAAGCTTCAAAATACGCC′3′, and pR2b: 5′CATTGGAACCTTGGGAGGCT′3′. The PCR products were analyzed on a 1% agarose gel in Tris-acetate-EDTA buffer. The PCR products were purified with QIAquick PCR purification kit (Qiagen Inc., USA) and subjected to Sanger sequencing at the Genomics Core Facility at AECOM supported by the Cancer Center Support Grant (P30 CA013330).

2.4 | Real Time Quantitative RT-PCR

Real-Time Quantitative Reverse Transcription PCR (Q-RT-PCR) for COSMC and T-synthase was performed at the Genomics Core Facility at AECOM. cDNA was prepared from 500 ng of total RNA using superscript vilo master mix (Invitrogen, USA). Real time Q-RT-PCR was performed using Taqman fast advanced master mix and primer probe mix (Life Technologies, USA) in an 8 µL reaction volume in 7900 HT Fast Real time PCR system (Applied Biosystems, USA) with Taqman assays (Supplementary Table 2) as per manufacturer’s instructions. The housekeeping gene used was 18S ribosomal RNA. The TaqMan assays were designed using Primer Express (Life Technologies, USA) and incubated on a rocker at 37°C for 2 hours prior to loading on a gel. Twenty amplicon sequences detected by the Taqman assays are provided in Table S3. Fold changes were calculated using the 2−ΔΔCt method and plotted as fold differences of relative expression normalized to controls.

2.5 | Western blotting

Brain homogenates were prepared by sonication using 1 g of cortex in 10 mL of lysis buffer [tris buffered saline, pH 7.4 with sodium fluoride, sodium orthovanadate, EGTA, Triton-X-100] containing complete mini protease inhibitor cocktail (Roche, USA). Supernatants were prepared by centrifugation of homogenates for 10 minutes at 4°C at 14,000 RPM in an Eppendorf 5418R centrifuge. Protein concentrations were measured using the Bradford assay (Biorad Laboratories, USA).21 Supernatants were heated at 55°C, whereas homogenates were heated at 95°C for 5 minutes prior to loading on a gel. Twenty micrograms protein was subjected to electrophoresis on NuPAGE 10% Bis-Tris protein gels and transferred to PVDF membranes (EMD Millipore, USA) using NuPAGE gel electrophoresis system (Invitrogen, USA). Membranes were blocked with 5% non-fat dry milk (Omnipur, Calbiochem, USA) in TBST (0.05% Tween 20) and incubated overnight at 4°C with primary antibodies. Brain homogenates were probed with rabbit anti-beta Amyloid D54D2 (Cell Signaling 1:2000), while supernatants were probed with mouse anti-COSMC H-10 (Santa Cruz 1:1000) and rabbit anti-C1GALT1: PA5-43363 (Invitrogen 1:1000). Secondary antibodies used were HRP anti-rabbit (Invitrogen 1:10000) or HRP anti-mouse (Millipore 1:2000). The results were visualized with chemiluminescence reagent (Kindle Bioscience; USA) and quantified by analyzing densitometry with ImageJ. Normalization was performed with anti-actin [mouse anti-actin (Calbiochem 1:7000) for COSMC and amyloid β [Aβ]; HRP anti-mouse mu chain specific (Invitrogen 1:10000) and rabbit anti-human actin (Invitrogen 1:1000) for T-synthase; HRP goat anti rabbit IgG (H+L) Abcam GR 3192715-6]. The mouse anti-actin antibody cross reacts with human actin as well as actin from several species.

2.6 | T-synthase activity assay

T-synthase activity was measured in supernatants from AD and normal brain tissue using a fluorescent assay developed by Ju and Cummings.22,23 Reagents for the assay included UDP-Gal as donor (Millipore Sigma, USA), GalNAc-α-(4-methylumbelliferone) (GalNAc-α-(4-MU)) as acceptor (Carbosynth Limited, UK), and 7-Hydroxy-4-MU (Alfa Aesar, USA). The reaction product was cleaved by endo-α-N-acetylglactosaminidase (New England Biolabs, USA) to release 4-methylumbelliferone (4-MU), which is fluorescent. To generate a standard curve, 4-MU was dissolved in DMSO to make a 1 mM stock solution, followed by dilutions in 0.5 mM MES-NaOH buffer (pH 6.8) to achieve a range of concentrations between 10 and 20,000 nM; 50 µL of each concentration was loaded in triplicate into a 96 well black plate (Corning, USA) and incubated on a rocker at 37°C for 2 hours prior to adding 100 µL of stop solution (1 M Glycine-NaOH, pH 10.0). The fluorescence was measured using a spectrophotometer (Molecular Devices, USA) at excitation and emission wavelengths of 355 and 460 nm, respectively.

For the assay, 10 µL supernatant was mixed with 1000 µM GalNAc-α-(4-MU), 500 µM UDP-Gal, 20 mM MnCl2, and 800 units of O-Glycosidase in 50 mM MES-NaOH buffer (pH 6.8) and incubated at 37°C for 2 hours on a rocker. Subsequently, 100 µL of stop solution was added and the fluorescence units were measured. In blank reactions deionized water replaced UDP-Gal.23 T-synthase activity was calculated as pmol/h-mg protein by dividing T-synthase activity (pmol/hr-mg) by the protein concentration (mg/mL) determined by Biorad assays.

2.7 | Statistical analysis

Statistical analysis was performed using SigmaStat (Systat Software). Analysis of variance (ANOVA) between the groups was performed. All P values ≤ 0.05 were statistically significant and denoted by *, whereas P values ≤ 0.01 were denoted by **.
TABLE 1  COSMC mutations in promoter, coding region and 3′UTR in Alzheimer’s disease and age-matched normal brain samples.

| Case number | Promoter | Coding region | 3′UTR |
|-------------|----------|---------------|-------|
| Normal 1    | None     | g.4376T>A, p.D131E ¶ | c.*237T>G |
| Normal 2    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | c.*237T>G |
| Normal 3    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | None |
| Normal 4    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | None |
| Normal 5    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | None |
| Normal 6    | g.-3044G>T + g.-3043G>T | g.4376T>A, p.D131E ¶ + g.4411C>T, p.A143V ¶ + homozygous g.4656_4657 insT, p.C226X ¶ ¶ | c.*132_133InsA + c.*237_238InsT + c.241_242InsA |
| Normal 7    | g.-3044G>T + g.-3043G>T | None | c.*23G>A + c.*87G>A |
| Normal 8    | g.-3044G>T + g.-3043G>T and homozygous g.-3018G>A | g.4589A>C, p.N202T ¶ ¶ | None |
| Normal 9    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | c.*235_236InsG |
| AD III-1    | g.-3044G>T + g.-3043G>T | None | None |
| AD III-2    | None | None | None |
| AD III-3    | None | g.4616,4617InsA + g.4643_4644 InsA, p.G212RfsX219 ¶ ¶ | None |
| AD III-4    | None | None | None |
| AD III-5    | g.-3044G>T + g.-3043G>T and g.-3018G>A | g.4936A>T, p.D318V ¶ ¶ | None |
| AD VI-1     | g.-3044G>T + g.-3043G>T | g.4376T>A, p.D131E ¶ | None |
| AD VI-2     | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | c.*22T>G + c.*87G>A |
| AD VI-3     | g.-3044G>T + g.-3043G>T | None | None |
| AD VI-4     | g.-3018G>A | None | None |
| AD VI-5     | None | g.4376T>A, p.D131E ¶ | None |
| AD VI-6     | g.-3044G>T + g.-3043G>T | g.4376T>A, p.D131E ¶ + g.1 G>T ¶ ¶ | c.*178T>G + c.*215A>C |
| AD VI-7     | g.-3044G>T + g.-3043G>T | g.4376T>A, p.D131E ¶ | None |
| AD VI-8     | g.-3044G>T + g.-3043G>T | None | c.*107_108InsA + c.*214_215InsA |
| AD VI-9     | g.-3044G>T + g.-3043G>T and g.-3018G>A | g.4588A>C, p.N202G ¶ ¶ | c.*137_138InsA + c.*177_178InsT |
| AD VI-10    | g.-3044G>T + g.-3043G>T and g.-3018G>A | None | None |
| AD VI-11    | g.-3044G>T + g.-3043G>T | Homozygous g.4376T>A, p.D131E ¶ | c.*218_219InsT |

¶¶ Are unique mutations and ¶ are mutations found in gnomAD database.

3  | RESULTS

3.1  | COSMC mutations in brain tissues

PCR of COSMC to amplify exon 1 and exon 2 from normal and AD brain tissues revealed that all groups had mutations in COSMC in varying percentages in promoter, coding region, as well as 3′UTR. No mutations were found in 5′UTR or exon 1 (Table 1).

3.1.1  | Promoter mutations

Substitution mutations at three unique locations in the COSMC promoter were found in common across AD and normal brain samples (Figure S1). Co-occurrence of three promoter mutations (g.-3044G>T, g.-3043G>T, and g.-3018G>A) was exhibited at a higher percentage in normal brain samples (56%) as compared to AD VI (27%). This is inverse to the co-occurrence of double promoter mutations (g.-3044G>T and...
3.1.2 Coding mutations

The mutations observed in normal, AD III, and AD VI are depicted in Figure 1A-H. A linear regression curve indicated that the percentage of coding mutations positively correlates with the progression of the disease ($R^2 = 0.9578$) (Figure 1I). The most frequently observed mutation in the coding region of COSMC was g.4376T>A, p.D131E, found in 45.5% of all AD VI and 22.2% of normals. Sample AD VI-6 also has a 3′ consensus splice site mutation (g.*1G>T) (Figure 1H). A single frameshift mutation in Sample AD III-3 due to two independent insertion events resulted in p.G212RfsX219 (Figure 1E).

3.1.3 3′UTR mutations

The percentage of 3′UTR mutations in normal and AD VI were 56% and 45% (Figure S2). None of the AD III samples had 3′UTR mutations.
60% of AD samples had double variations in 3′UTR, which included double substitutions or double insertion events (Figure S2E-I). The AD VI samples that expressed 3′UTR variations were surprisingly homozygous in AD VI (Figure S2F-I) except for AD VI-2, which was heterozygous (Figure S2E). The normal brains also had 3′UTR mutations (Figure S2A-D). Normal-6 had homozygous insertions (Figure S2A) unlike the rest of the normals with heterozygous variations (Figure S2B-D).

In summary, the frequency of COSMC mutations in the prefrontal cortex of AD brains was almost twice that of normal brains. A linear regression curve indicated that the number of mutations increased with AD progression.

3.2 | Q-RT-PCR of T-synthase and COSMC

Taqman assays were performed to investigate differences in RNA expression of COSMC and T-synthase in AD and normal brains using 18S as housekeeping gene. COSMC RNA expression demonstrated a trend: AD VI < AD III < Normals (Figure 2). AD VI and AD III had 4.2-fold and 1.2-fold lower COSMC expression, respectively, as compared to normals. The expression of T-synthase between the groups did not demonstrate a trend. The expression levels between the groups were not significantly different for either COSMC or T-synthase. In summary, COSMC mutations did not significantly reduce expression of COSMC or T-synthase RNA expression.

3.3 | Western blot

Western blot analysis was performed using antibodies against COSMC, T-synthase, and Aβ antibodies to examine the effects of COSMC coding mutations on these proteins. There were no significant differences in COSMC protein expression between the normal, AD III, or AD VI brains with and without mutations (Figure 3A and B).

T-synthase antibody revealed protein monomers at 52 kDa and dimers at 102 kDa (Figure 3C). ImageJ analysis of pooled bands revealed significantly higher T-synthase levels in advanced AD with mutations as compared to normals with mutations (P = 0.03) and normals without mutations (P = 0.01) (Figure 3D). Analyzing the dimer band independently in samples with mutations, advanced AD had higher levels compared to normals (P = 0.034). In addition, in samples without mutations, advanced AD exhibited higher T-synthase levels compared to normals and AD III (Figure 3D). In all samples without factoring COSMC coding mutations, advanced AD again exhibited significantly higher T-synthase levels compared to normals (P = 0.0028) and AD III (P = 0.032) (Figure 3E).

The Aβ antibody was used to investigate a possible relationship with COSMC (Figure 4A). The 4 kDa Aβ band was significant in AD III (P = 0.001) and AD VI (P = 0.046) when compared to normals without COSMC coding mutations (Figure 4B). The high-molecular-weight Aβ multimers were also present in all AD samples (Figure 4A). Three normal samples with mutations classified as normal and without significant neuropathology, displayed a 4 kDa Aβ band at levels comparable to AD brain samples and significantly higher than normals without mutations (P = 0.047) (Figure 4A). In addition, these samples also had the same mutations as observed in AD VI. In conclusion, COSMC coding mutations did not significantly influence COSMC but resulted in an elevation of T-synthase protein in advanced AD.

3.4 | T-synthase activity assay

T-synthase activity was measured in supernatants to determine the effects of COSMC mutations on T-synthase (Figure 5). No significant differences in T-synthase activity were observed when results were compared without factoring coding mutations. Separating the groups based on presence or absence of COSMC coding mutations revealed a significant difference. The AD VI without COSMC coding mutations had 3.1-fold higher T-synthase activity when compared to AD VI with coding mutations (P = 0.01). In addition, in the presence of coding mutations, AD VI had significantly lower T-synthase activity as compared to both AD III (P = 0.03) and normal brain (P = 0.001). T-synthase activity in AD VI with COSMC coding mutations were significantly lower as compared to AD III and normal with mutations as well as AD VI without COSMC coding mutations.

4 | DISCUSSION

Based on previous findings that glycoprotein abnormalities may play a role in LOAD pathogenesis, this study focused on COSMC gene mutations and T-synthase activity, the essential factors in biosynthesis and integrity of mucin type glycoproteins. Common genetic variations in these genes can influence O-glycosylation. This is the first report
FIGURE 3  Western blot and ImageJ analysis in normal, AD III, and AD VI brain samples with and without COSMC coding mutations. (A) Western analysis with COSMC and actin antibodies. (B) ImageJ analysis of COSMC western blot. (C) Western analysis with T-synthase and actin antibodies and (D) ImageJ analysis of T-synthase western blot. + are with COSMC coding mutation and - are without COSMC coding mutation. * represents significance at $P \leq 0.05$ and ** represents significance at $P \leq 0.01$. (E) ImageJ analysis of T-synthase western blot irrespective of COSMC coding mutations. * represents significance at $P \leq 0.05$ and ** represents significance at $P \leq 0.01$

on COSMC mutations in the coding region, promoter region, and 3′UTR in both AD and normal brains.

In the coding region, the p.D131E was the most common mutation observed in 22.2% of normals and 45.45% of advanced AD subjects. This SNP, formerly known as c.628T > A [ncbi: s17261572], was reported in 32% of 120 healthy Europeans.26 A functional role of this SNP had not yet been established with any human diseases. T-synthase protein levels in advanced AD were higher than normals and AD III, probably due to the failure of clearance of aggregated and misfolded proteins.26 In the absence of COSMC in cultured cells, T-synthase protein cannot fold to become active and aggregates.27 The binding of COSMC to sequester T-synthase to promote its folding may prevent
T-synthase from forming oligomers. We observed T-synthase monomers and dimers and low T-synthase activity indicative of dysfunctional COSMC and the likely inability of COSMC to sequester T-synthase protein.

Our observations indicate that COSMC coding mutations influence T-synthase activity without altering COSMC protein levels. The supernatants prepared from the brain tissues without coding mutations exhibited 3.1-fold higher T-synthase activity compared to normal brains with coding mutations. Comparing the coding mutation positive cases, advanced AD had significantly lower T-synthase activity compared to AD III and normals despite significantly higher T-synthase protein. This supports the conclusion that reduced T-synthase activity in AD with COSMC coding mutations is due to failure of COSMC activation of T-synthase. The effects of COSMC mutations on T-synthase activity in normals and advanced AD are different. We presume that these differences are related to the pathological changes in AD brain: the mutant COSMC protein can activate T-synthase in a normal brain environment but cannot function in the pathological environment in the advanced AD. This effect of the environment may also explain why no effects had been previously recognized for p.D131E mutation, which was tested only in normals.26

COSMC mutations resulting in Tn antigen expression have been shown to cause several diseases.16,28 However, in vivo and in vitro effects of COSMC mutations may differ. Two COSMC mutant proteins p.Δ256 and p.E152K are functional in vitro; however, p.E152K shows loss of function and increased Tn antigen expression in vivo.28,29 COSMC p.E152K mutation, originally identified in polyagglutinability syndrome, was not observed in our study. Loss of functional COSMC by mutation, deletion, or hypermethylation may contribute to Tn expression. For a better understanding of the role of COSMC mutations in the pathophysiology of LOAD functional studies are necessary considering the complex interplay between genes and environment in aging brains.

Aging has been shown to increase somatic mutation, which may be responsible for late-onset neurodegenerative diseases like AD.30,31 In our cohort, the average age of the Duke AD samples was 17 years younger than that of NSW AD samples, whereas the average age of the Duke normal brains was 10 years younger than that of NSW normal brains. These age differences may account for the higher mutation incidence observed in the NSW samples. Given that the COSMC protein levels did not differ between the groups with and without mutations, it suggests that brain COSMC mutations have a somatic origin.

COSMC is located on the X-chromosome and in this study several female subjects had homozygous variations (Table 1). Two of the NSW females, normal-6 and normal-8 (ages 102 and 97), had the same COSMC coding mutations as advanced AD cases and significantly higher amounts of Aβ (Figure 4). The pathological determination of AD, however, is not solely dependent upon amyloid accumulation. As seen in many studies, age-matched individuals who are
cognitively normal have high amyloid deposits comparable to AD subjects.22 The updated National Institute on Aging and the Alzheimer’s Association’s neuropathological guidelines acknowledge the potential disconnect between the clinical picture and neuropathological changes.32-34

Similar to the coding region, SNPs and modifications in the promoter region can cause changes in the expression of COSMC.35,36 In our study, three SNPs g.-3044G>T, g.-3043G>T, and g.-3018G>A were observed in COSMC promoter. SNP g.-3018G>A (rs3810744) has been reported in IgA nephropathy, a disorder that also expresses Tn antigen.27 Future studies should explore the relevance of COSMC promoter mutations in AD. Both COSMC and T-synthase are under the control of Krüppel-like transcription factors (TFs), the expression of which varies substantially in different tissues.36 The Krüppel-like factors (KLFs), including SP1/SP3, are a family of ubiquitously expressed proteins that regulate target gene transcription.36 Basal levels of human COSMC and T-synthase are transcriptionally regulated by KLF SP1/3 TFs and regulate other cell- or tissue-specific TFs. Several glycosyltransferases involved in O-glycan biosynthesis are also under the control of SP1. Reporting for the first time, the unique COSMC promoter mutations at g.-3043 and g.-3044 fall in the KLF region and probably contribute to the variable expression of COSMC and T-synthase, which needs further investigation.

COSMC 3′UTR has binding sites for multiple micro RNAs (miRNAs) such as hsa-miR-448 as predicted by www.targetscan.org. The miRNAs bind to 3′UTR and regulate gene expression mediated by miRNA response elements (MREs). SNPs in 3′UTR contribute to disease pathogenesis including AD.38,39 In LOAD, 35 miRNAs in the hippocampus and 41 miRNAs in the prefrontal cortex are deregulated.40 In LOAD, three MRE-SNPs in 3′UTRs of the genes; TF CP2, granulin, and insulin degrading enzyme alter their binding to miRNAs.41 In another study, miR-374 levels were significantly diminished in AD, which may target the AD gene beta-secretase 1 (BACE1).42 However, the significance of our 3′UTR mutations in miRNA binding in LOAD and glycoproteome needs further analysis.

Brains of AD patients display an altered profile of protein O-glycosylation, sialylation, and N-glycosylation.43,44 Both O-GlcNAcylation and O-GalNAcylation have been found to play a role in AD.45,46 Many of the AD-related proteins, including APP, TAU, BACE1, nicastrin, are functionally modified by glycosylation in AD pathogenesis.43,47-49 The interplay between Tn antigen, T antigen, COSMC, T-synthase, and sialylation needs further exploration in AD. Taken together, our results demonstrate that in advanced AD the COSMC coding mutations cause a significant reduction of T-synthase activity. The effects may be mediated through reduced galactosylation. There exists a need for evaluation of a larger number of AD patients for mutations in COSMC to establish an association with AD.

ACKNOWLEDGMENTS
This project was supported by Mr. Jeffrey and Mrs. Marieke Rothschild.

DECLARATIONS OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Cruchaga C, Del-Aguita JL, Saef B, et al. Polygenic risk score of sporadic late-onset Alzheimer’s disease reveals a shared architecture with the familial and early-onset forms. Alzheimers Dement. 2018;14(2):205-214.
2. Giau VV, Senanarong V, Bagyinszky E, An SSA, Kim S. Analysis of 50 neurodegenerative genes in clinically diagnosed early-onset Alzheimer’s disease. Int J Mol Sci. 2019;20(6):1514.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer disease in late onset families. Science. 1993;261(5143):921-923.
4. Durmaz A, Kurmal E, Durmaz B, et al. Genetic factors associated with the predisposition to late onset Alzheimer’s disease. Gene. 2019;707:212-215.
5. Schedin-Wiss S, Winblad B, Tjernberg LO. The role of protein glycosylation in Alzheimer disease. FEBS J. 2014;281(1):46-62.
6. Regan P, McClean PL, Smyth T, Doherty M. Early stage glycosylation biomarkers in Alzheimer’s disease. Medicines. 2019;6(3):92.
7. Lalezari P, Lekhraj R, Kimiabksh B, Carrasco E, Casper D. Tn antigen in the brain: a newly recognized glycophoprotein in Alzheimer’s disease. Alzheimer’s & Dementia. 2013;9(4, Supplement):P347-P348.
8. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature. 2005;437(7063):1252.
9. Ju T, Otto VI, Cummings RD. The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl. 2011;50(6):1770-1791.
10. Wells L, Feizi T. Editorial overview: carbohydrates: O-glycosylation. Curr Opin Struct Biol. 2019;56:iii-v.
11. de las Rivas M, Lira-Navarrete E, Gerken TA, Hurtado-Guerrero R. Polypeptide GalNAc-Ts: from redundancy to specificity. Curr Opin Struct Biol. 2019;56:87-96.
12. Aryal RP, Ju T, Cummings RD. Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and client-driven dissociation. J Biol Chem. 2012;287(19):15317-15329.
13. Wang Y, Ju T, Ding X, et al. Cosmc is an essential chaperone for correct O-glycosylation. Proc Natl Acad Sci U S A. 2010;107(20):9228-9233.
14. Crew VK, Singleton BK, Green C, Parsons SF, Daniels G, Anstee DJ. New mutations in C1GALT1C1 in individuals with Tn positive phenotype. Br J Haematol. 2008;142(4):657-667.
15. Berger EG. Tn-syndrome. Biochim Biophys Acta. 1999;1455(2):255-268.
16. Ju T, Wang Y, Aryal RP, et al. Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl. 2013;7(9-10):618-631.
17. Frenkel-Pinter M, Shmueli MD, Raz C, et al. Interplay between protein glycosylation pathways in Alzheimer’s disease. Sci Adv. 2017;3(9):e1601576.
18. van Tol W, Wessels H, Lefeber DJ. O-glycosylation disorders pave the road for understanding the complex human O-glycosylation machinery. Curr Opin Struct Biol. 2019;56:107-118.
19. Pericak-Vance M. Whole Exome Analysis of Early Onset Alzheimer’s Disease. University of Miami: Miami, United States; 2018. https://apps.dtic.mil/dtic/tr/fulltext/u2/1064060.pdf.
20. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer’s disease: microarray correlation analysis reveals major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101(7):2173-2178.
21. Maruszak A, Murphy T, Liu B, De Lucia C, Davieru A, Nevado AJ, Teu-
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
23. Ju T, Cummings RD. A fluorescence-based assay for Core 1 beta3galactosyltransferase (T-synthase) activity. Methods Mol Biol. 2013;1022:15-28.
24. Ju T, Xia B, Aryal RP, et al. A novel fluorescent assay for T-synthase activity. Glycobiology. 2011;21(3):352-362.
25. Kiryluk K, Li Y, Moldoveanu Z, et al. GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet. 2017;13(2):e1006609.
26. Gale DP, Molyneux K, Wimbury D, et al. Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol. 2017;28(7):2158-2166.
27. Malycha F, Eggermann T, Hristov M, et al. No evidence for a role of cosm-c/mero-chaperone mutants in European IgA nephropathy patients. Nephrol Dial Transplant. 2009;24(1):321-324.
28. Aryal RP, Ju T, Cummings RD. Identification of a novel protein binding motif within the T-synthase for the molecular chaperone Cosmc. J Biol Chem. 2014;289(17):11630-11641.
29. Sun X, Ju T, Cummings RD. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer. 2018;18(1):827.
30. Hanes MS, Moremen KW, Cummings RD. Biochemical characterization of functional domains of the chaperone Cosmc. PLoS One. 2012;7(6):e180242.
31. Park JS, Lee J, Jung ES, et al. Brain somatic mutations observed in Alzheimer’s disease associated with aging and dysregulation of tau phosphorylation. Nat Commun. 2019;10(1):3090.
32. Lodato MA, Walsh CA. Genome aging: somatic mutation in the brain links age-related decline with disease and nomimates pathogenic mechanisms. Hum Mol Genet. 2019;28(R2):R197-R206.
33. Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25(1):59-70.
34. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1-13.
35. Meccoci P, Baroni M, Senin U, Boccardi V. Brain aging and late-onset Alzheimer’s disease: a matter of increased amyloid or reduced energy. J Alzheimers Dis. 2018;64(s1):S397-S404.
36. Liu Y, Wang M, Marcora EM, Zhang B, Goate AM. Promoter DNA hypermethylation—Implications for Alzheimer’s disease. Neurosci Lett. 2019;711:134403.
37. Zeng J, Mi R, Wang Y, et al. Promoters of human Cosmc and T-synthase genes are similar in structure, yet different in epigenetic regulation. J Biol Chem. 2015;290(31):19018-19033.
38. Li GS, Nie GJ, Zhang H, Lv JC, Shen Y, Wang HY. Do the mutations of C1GALT1C1 gene play important roles in the genetic susceptibility to Chinese IgA nephropathy. BMC Med Genet. 2009;10:101.
39. Le MT, Xie H, Zhou B, et al. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol. 2009;29(19):5290-5305.
40. Juzwik CA, S SD, Zhang Y, et al. microRNA dysregulation in neurodegenerative diseases: a systematic review. Prog Neurobiol. 2019;182:101644.
41. Lau P, Bossers K, Janky R, et al. Alteration of the microRNA network during the progression of Alzheimer’s disease. EMBO Mol Med. 2013;5(10):1613-1634.
42. Roy J, Mallick B. Altered gene expression in late-onset Alzheimer’s disease due to SNPs within 3’UTR microRNA response elements. Genomics. 2017;109(3):177-185.
43. Manzine PR, Pelucchi S, Horst MA, et al. microRNA 211 targets ADAM10 mRNA and is downregulated in Alzheimer’s disease. J Alzheimers Dis. 2018;61(1):113-123.
44. Kanninen K, Goldsteins G, Auriola S, Alafuzoff I, Koistinaho J. Glycosylation changes in Alzheimer’s disease as revealed by a proteomic approach. Neurosci Lett. 2004;347(2):235-240.
45. Butterfield DA, Owen JB. Lectin-affinity chromatography brain glycoproteomics and Alzheimer disease: insights into protein alterations consistent with the pathology and progression of this dementing disorder. Proteomics Clin Appl. 2011;5(1-2):50-56.
46. Wani WY, Chatham JC, Darley-Ushar V, McMahon L, Zheng J. O-GlcNAcylation and neurodegeneration. Brain Res Bull. 2017;133:80-87.
47. Akasaka-Manya K, Kawamura M, Tsumoto H, et al. Excess APP O-glycosylation by GaINAc-T6 decreases Ap production. J Biochem. 2016;161(1):99-111.
48. Kizuya Y, Kitazume S, Fujinawa R, et al. An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer’s disease. EMBO Mol Med. 2015;7(2):175-189.
49. Lassen PS, Thygesen C, Larsen MR, Kempf SJ. Understanding Alzheimer’s disease by global quantification of protein phosphorylation and sialylated N-linked glycosylation profiles: a chance for new biomarkers in neuroproteomics. J Proteomics. 2017;161:11-25.
50. Taniguchi N, Takahashi M, Kizuya Y, et al. Glycation versus glycosylation: a tale of two different chemistries and biology in Alzheimer’s disease. Glycoconj J. 2016;33(4):487-497.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Gollamudi S, Lekhraj R, Lalezari S, Lalezari P. COSMC mutations reduce T-synthase activity in advanced Alzheimer’s disease. Alzheimer’s Dement. 2020;6:e12040. https://doi.org/10.1002/trc2.12040